

## Subject Index

**A**quired immunodeficiency  
syndrome, murine, 822-834

ACTH, 249-261, 456-469

acute-phase response, 787-802

adaptation, 39-44

adjuvant arthritis, 599-607

$\alpha$ -adrenergic receptors, 185-193,  
698-704

$\beta$ -adrenergic receptor mRNA, 204-248

afferent pyrogenic signaling, 608-618

African trypanosomiasis, 809-821

aging, 491-497, 848-856

allergic inflammation, 747-754

allostasis, 39-44

allostatic load, 39-44

$\gamma$ -aminobutyric acid (GABA), 174-184,  
185-193

antagonist, 338-351

anterior pituitary  
function of, 525-531  
growth of, 525-531

antibody-secreting cell responses,  
803-808

anticancer therapy, 411-419

antiinflammatory action, 373-380

apoptosis, 518-524, 835-847

arthritis, 1-8, 698-704

astroglial cytokines, 204-248

atopic dermatitis, 747-754

autoantigens, neuroendocrine, 328-337

autocrine regulation, 525-531

autoimmune disease, 591-598

autoimmunity, 45-50, 591-598,  
762-772

autonomic reactivity, 664-673

AVP. *See* vasopressin

**B**ehavior, 577-585, 586-590

behavioral research, 563-576

bicuculline, 174-184

bladder disorder, 619-634

body temperature, 444-455

bone density, 717-722

bone formation, 194-204

bone resorption, 194-204

bone marrow stroma, 411-419

brain, 123-127, 289-300, 310-316

**C**alcitonin gene-related peptide,  
551-562

cancer, psychosocial treatments,  
674-683

cancer survival, 674-683

carbon monoxide, 249-261

caspases, 59-64

catecholamines, 153-161, 698-704

CCK. *See* cholecystokinin

central nervous system, 1-8

chemokine-induced chemotaxis, 9-20

cholecystokinin, 586-590

chronic stress, 444-455

chronic fatigue syndrome, 684-697

circadian rhythm, 491-497

colonic responses, stress-mediated,  
635-648

colony-stimulating factors (CSFs),  
352-358

compartmental immune responses,  
540-550

complement, 608-618

conflict, 656-663

contact hypersensitivity reactions,  
381-394

corticosterone, 117-122, 705-716,  
773-786

corticotropin-releasing factor, 635-648  
action of, 162-173

corticotropin-releasing hormone  
(CRH), 174-184, 249-261, 444-455,  
635-648, 717-722

**CRH neuron**

- IL-1, 65-73
- long-lasting effect, 65-73
- plasticity, 65-73
- responsiveness, 65-73
- vasopressin, 65-73

cortisol, 717-722

CRH. *See* corticotropin-releasing hormone

Crohn's disease, 723-734

cutaneous immunomodulation, 381-394

cyclic AMP, 420-424, 698-704

cyclooxygenase, 174-184, 185-193

cytokines, 1-8, 45-50, 117-122,

123-127, 153-161, 204-248,

289-300, 338-351, 577-585,

698-704, 705-716, 735-746 809-821

brain, 586-590

CNS pathobiology of, 83-96

expression of, 525-531

increased levels of, 434-443

transgenic expression of in CNS,  
83-96

**DADLE, 420-424**

l-deprenyl, neurorestoration with,  
262-268

depression, 1-8, 717-722

dimerization, 498-509

2,4-dinitro-1-fluorobenzene (DNFB),  
359-372

DNFB. *See* 2,4-dinitro-1-fluorobenzene  
dopamine, 123-127, 174-184

**Encephalopathy, 822-834**

endocrinology, thymic, 352-358

$\beta$ -endorphin, 185-193, 420-424

endotoxin, 139-152, 249-261, 444-455

endotoxin i.v., 608-618

endotoxin (lipopolysaccharide),  
577-585

endotoxin shock, 787-802

experimental autoimmune

encephalomyelitis (EAE), 705-716

**Febrile illness, 787-802**

feeding, 577-585

feto-placental interphase, 204-248

fever, 51-58, 444-455, 787-802

fibromyalgia, 684-697

follicle-stimulating hormone (FSH),  
185-193

**Gap junctions, 470-479**

glucocorticoids, 21-32, 456-469,  
705-716, 735-746

action, counterregulation of, 74-82

biosynthesis, 317-327

hormones, 591-598

receptor, 735-746

receptor mRNA, 204-248

resistance, 835-847

glucose, 153-161

glycogen, 153-161

glycosaminoglycan layer, bladder,  
619-634

gp130, 194-204

granulocyte-macrophage colony-  
stimulating factor (GMCSF),  
174-184

granuloma, 532-539

growth factors, 97-106, 204-248

growth hormone, 470-479, 510-517

guanylate cyclase, 174-184, 185-193

**Hapten-specific tolerance, 381-394**

hematopoiesis, 411-419

hematopoietic cells, 97-106

hematopoietic progenitor cells,  
518-524

hippocampus, 139-152, 444-455

HIV infection, 848-856

hormones, 45-50, 762-772

hostility, 656-663

HPA axis. *See* hypothalamic-  
pituitary-adrenal axis

human pheochromocytomas, 425-433

hypersensitivity, delayed-type, 359-372

hypothalamic-pituitary-adrenal axis,  
1-8, 352-358, 434-443, 444-455,  
480-490, 591-598, 599-607,  
773-786, 835-847  
dysfunctional, 747-754  
dysregulation, pathophysiologic  
implications of, 684-697  
hyperresponsiveness, 65-73  
reactivity of, 664-673  
response to IL-1, 65-73  
stimulation of by immune signals,  
434-443  
stress, 65-73  
hypopituitarism, 809-821  
hypothalamic, 21-32  
hypothalamic-hypophyseal-gonadal-  
thymic axis (HHGTA), 204-248  
hypothalamus, 249-261  
preoptic, 269-281  
ventromedial, 269-281

**I**CE. *See* interleukin-1 $\beta$ -converting  
enzyme  
immune, 21-32  
immune reconstitution, 480-490  
immune response, 204-248  
immune system, 762-772  
immunity, 649-655  
cell-mediated, 359-372  
immunocompetent cells, 510-517  
immunocytochemistry, 123-138  
immunomodulation, 498-509,  
803-808  
immunoneuroendocrinology, 480-490  
individual differences, 664-673  
indomethacin, 577-585  
infectious disease, 787-802  
inflammation, 9-20, 21-32, 338-351  
neurogenic, 282-288  
inflammatory bowel disease, 723-734  
inflammatory, infectious disease host  
susceptibility factors, 1-8  
inositol triphosphate, 420-424  
insulin growth factor-I, 518-524

interdisciplinary, 563-576  
interferon- $\alpha$ , 835-847  
interferon- $\gamma$ , 352-358, 532-539  
interleukin, pain modulatory actions,  
269-281  
interleukin-1, 51-58, 59-64, 128-138,  
139-152, 174-184, 269-281, 289-300,  
338-351, 577-585, 586-590  
actions in the brain, 65-73  
HPA system, 65-73  
long-lasting effects, 65-73  
neuroplasticity, 65-73  
interleukin-1 mutants, 51-58  
interleukin-1 receptor, 755-761  
interleukin-1 receptor antagonist,  
123-138, 153-161, 577-585  
interleukin-1 $\beta$ , 425-433, 456-469  
interleukin-1 $\beta$ -converting enzyme,  
51-58, 59-64  
interleukin-2, 174-184  
interleukin-3 receptors, 107-116  
interleukin-3, 107-116  
interleukin-6, 269-281, 310-316  
interstitial cystitis, 619-634  
intracellular calcium, 420-424

**K**AT45 human pheochromocytoma  
cell line, 425-433  
knock-out, 498-509  
knockout mice, 51-58  
and IL-1 $\beta$ , 51-58  
and IL-1RI, 51-58  
Kupffer cells, 608-618

**L**eukemia, 97-106  
leukemia inhibitory factor, 162-173  
leukocyte trafficking, 359-372  
leukotrienes, 185-193  
LHRH, *See* leuteinizing hormone-  
releasing hormone  
lipopolysaccharide (LPS), 123-138,  
289-300, 586-590  
lipopolysaccharide, bacterial, 174-184  
lipoxigenase, 174-184

lung, 735-746  
luteinizing hormone (LH), 185-193  
luteinizing hormone (LH)-releasing hormone, 174-184, 185-193, 205-248, 586-590  
luteinizing hormone-releasing hormone (LHRH) receptors, 204-248  
lymphocytes, 359-372, 540-550  
lymphocytic meningoencephalomyelitis, 83-96  
lymphoid organs, sympathetic noradrenergic innervation of, 262-268

**M**acrophage migration inhibitory factor (MIF), 74-82  
macrophages, 540-550  
  release of MIF, 74-82  
marriage, 656-663  
 $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ MSH), 269-281, 373-380, 381-394  
  administration in humans, 848-856  
melanosis, 835-847  
melatonin, 411-419, 491-497  
melatonin rhythms  
  in mice, 395-410  
  role in autoimmune diseases, 395-410  
  role in lymphoproliferative diseases, 395-410  
Met-enkephalin, 9-20  
metabolic bone diseases, 194-204  
mice  
  inbred New Zealand black (NZB), 762-772  
  NZB autoimmune, 755-761  
  transgenic, 705-716  
microglia, 59-64  
MIP-15, 456-469  
mRNA stability, 773-786  
 $\alpha$ -MSH. *See*  $\alpha$ -melanocyte-stimulating hormone

multilevel research, 563-576  
multiple sclerosis, 717-722  
murine leukemia virus, 822-834  
murine acquired immunodeficiency syndrome, 822-834  
murine systemic lupus erythematosus (SLE), 599-607  
mycobacteria, 773-786  
myelin basic proteins (MBP), 705-716  
myocardial infarction, 848-856  
**N**altrexone, 185-193  
National Institutes of Health, 563-576  
natural immunity, 787-802  
necrosis apoptosis, 59-64  
neonatal, 123-127  
neuroendocrine, 1-8  
neuroendocrine hormone, 705-716  
neuroendocrine dysfunction, 809-821  
neuroendocrine system, 551-562  
neuroimmune, 1-8  
neuroimmune host defense, 787-802  
neuroimmune pathways, 674-683  
neuroimmunity, 301-316  
neuroimmunomodulation, 301-316  
neuroimmunoregulation, 787-802  
neurons, central cholinergic, 107-116  
neuropeptide, 21-32  
neuroplasticity  
  CRH neuron, 65-73  
  IL-1 induced, 65-73  
  neuropeptide expression, 65-73  
neuropoietic cytokines, 97-106  
neurotensin, 635-648  
neurotrophins, 97-106  
newborn, 117-122  
NIH. *See* National Institutes of Health  
nitric oxide, 204-248, 249-261  
nitric oxide synthase (NOS), 174-184, 185-193  
nitroprusside, 185-193  
nociceptors, primary afferent, 282-288  
nonspecific illness symptoms, 123-138  
noradrenaline, 139-152

norepinephrine, 185-193  
  age-related changes in lymphoid  
    organs, 262-268  
NOS. *See* nitric oxide synthase  
Nramp1, 773-786  
nude mice, 480-490  
nurse cells, 328-337

**O**BSSR. *See* Office of Behavioral and  
  Social Research  
Office of Behavioral and Social  
  Research, 563-576  
opioid cytokines, 411-419  
organum vasculosum laminae  
  terminalis, 608-618  
osteoporosis, 194-204  
ovulation, 619-634  
oxytocin, 174-184

**P**ain  
  analgesia, 269-281  
  hyperalgesia, 269-281  
  paracrine regulation, 525-531  
  peripheral nerves, 289-300  
  pineal gland, 491-497  
  pineal grafting, 491-497  
  pituitary, 21-32, 249-261  
  plasma corticosterone, 359-372  
  plasma extravasation, venular, 282-288  
  POMC, 456-469  
  postganglionic sympathetic neuron  
    (PGSN) terminal, 282-288  
  pregnancy, 45-50  
  preoptic area, 139-152  
  prepro-thyrotropin-releasing hormone  
    (178-179), 456-469  
  prepro-TRH. *See* prepro-thyrotropin-  
    releasing hormone  
  prolactin, 470-479, 498-509, 762-772  
  proopiomelanocortin, transcription of,  
    162-173  
  prostaglandin E<sub>2</sub> (EP), 185-193,  
    608-618

  pain modulatory actions, 269-281  
  receptors, 269-281  
  prostaglandins, 139-152  
  psychoneuroimmunology, 656-663

**R**at brain, 123-138  
receptors, 338-351  
  growth hormone, 510-517  
  IL-1, 51-58  
  membrane bound, 498-509  
rheumatoid arthritis, 45-50, 456-469,  
  848-856

**S**chistosomiasis, 532-539  
septic syndrome, 848-856  
serotonin, 139-152, 444-455  
sex steroids, 194-204  
sexual dimorphism, 204-248  
sickness behavior, 1-8, 444-455  
signal transduction, 498-509  
skin stress responses, 381-394  
SLE. *See* systemic lupus erythematosus  
sleeping sickness, 809-821  
social support, 674-683  
sociobehavioral research, 563-576  
somatostatin, 532-539  
spleen, 551-562  
  age-related changes in, 262-268  
  steroids, 735-746  
  thymus-derived, 317-327  
stress response, 1-8  
stress  
  and cell-mediated immunity,  
    359-372  
  chronic, 599-607  
  intestinal responses to, 635-648  
  psychological, 649-655, 664-673  
  restraint, 705-716, 803-808  
  sensitization, 65-73  
  stress hormones, 656-663  
  substance P, 532-539, 586-590  
  sympathetic activity, 664-673  
  sympathetic ganglia, 123-127

sympathetic nervous system, 698-704  
systemic lupus erythematosus, 45-50,  
762-772

**T** cells, 735-746  
activation of, 510-517  
development of, 551-562  
education in neuroendocrine self  
principles, 328-337  
formation of, 317-327  
release of MIF, 74-82  
regulation of function of, 551-562  
T-cell receptor, 317-327  
T-cell responses, 803-808  
T-cell selection, 591-598  
T-helper cells, 411-419  
T-helpers, 835-847  
T lymphocytes, 328-337, 480-490  
thymic aging, 518-524  
thymic epithelial cells, 470-479  
thymic hormones, 204-248  
thymocytes, 352-358, 470-479  
thymosin- $\alpha_1$ , 352-358  
thymus, 204-248, 317-327, 328-337,  
352-358, 470-479, 551-562, 591-598  
age-related changes in, 262-268

thyroid hormones, 456-469  
TNF. *See* tumor necrosis factor.  
TRH, 491-497  
tuberculosis, 773-786  
tumor necrosis factor (TNF), 269-281,  
289-300  
tumor necrosis factor- $\alpha$ , 310-316

**U**lcerative colitis, 723-734

**V**accine, hepatitis B, 649-655  
vaccine, influenza virus, 649-655  
vagal mediation, 608-618  
vagus nerve, 289-300, 586-590  
vasoactive intestinal peptide,  
540-550  
vasopressin, 249-261, 717-722  
CRH neuron, 65-73  
expression of, 65-73  
response to IL-1, 65-73  
secretion of, 65-73  
viral infection, 803-808

**Z**inc-thymulin, 352-358

## Index of Contributors

**A**chour, I., 328-337

Airaghi, L., 848-856

Aird, F., 456-469

Alheim, K., 51-58

Allen, S. H., 762-772

Allolio, B., 809-821

Alves, L. A., 470-479

Anderson, N. B., 563-576

Anton, P. A., 723-734

Aou, S., 269-281

Arlt, W., 809-821

Arzt, E., 525-531

Ashwell, J. D., 317-327

**B**aird, S., 551-562

Bartfai, T., 51-58

Basile, A. S., 822-834

Becher, E., 381-394

Ben-Baruch, A., 9-20

Berczi, I., 787-802

Berntson, G. G., 664-673

Besedovsky, H. O., 117-122, 123-127,  
153-161

Bevilacqua, M., 835-847

Binart, N., 498-509

Blatteis, C. M., 608-618

Bluthé, R.-M., 586-590

Bole-Feysot, C., 498-509

Bouchard, B., 498-509

Boxer, P. A., 59-64

Bret-Dibat, J.-L., 586-590

Brown, D. H., 773-786

Brzoska, T., 381-394

Bucala, R., 74-82

Bullock, K., 551-562

Burgess, W., 518-524

Burleson, M. H., 664-673

Buske-Kirschbaum, A., 747-754

**C**acioppo, J. T., 656-663, 664-673

Campbell, I. L., 83-96

Castagliuolo, I., 635-648

Catania, A., 373-380, 848-856

Chew, S. L., 249-261

Chrousos, G. P., 21-32, 735-746,  
809-821

Chu, X., 803-808

Chui, D.-H., 107-116

Clement-LaCroix, P., 498-509

Clerici, M., 835-847

Colotta, C., 338-351

Conti, A., 395-410

Costa, A., 249-261

Costas, M., 525-531

Crofford, L. J., 684-697

Crumeyrolle-Arias, M., 755-761

Cutuli, M., 848-856

**D**ahia, P. L. M., 249-261

Daneva, T., 480-490

Dantzer, R., 518-524, 586-590

Dardenne, M., 470-479, 510-517

de Castro, M., 735-746

de Jong-de Vos van Steenwijk, T.,  
698-704

del Rey, A., 117-122, 123-127, 153-161

Demitrack, M. A., 684-697

Dhabhar, F. S., 359-372

Diwa, A., 551-562

Dobbs, C., 803-808

Dowdell, K., 705-716

Dunn, A. J., 577-585

**E**dery, M., 498-509

Elenkov, I. J., 21-32

Elliott, D., 532-539

Ernst, J. M., 664-673

**F**an, J.-P., 107-116  
 Farinella, Z., 205-248  
 Felten, D. L., 262-268  
 Ferrag, F., 498-509  
 Fleshner, M., 289-300  
 Forsling, M. L., 249-261  
 Franchimont, D., 328-337  
 Furukawa, H., 117-122, 123-127

**G**abellec, M.-M., 755-761  
 Gagnerault, M. C., 510-517  
 Gaillard, R. C., 480-490  
 Gallo, F., 205-248  
 Garofalo, L., 848-856  
 Gaufo, G. O., 540-550  
 Geenen, V., 328-337  
 Glaser, R., 649-655, 656-663, 664-673, 803-808  
 Goehler, L. E., 289-300  
 Goetzl, E. J., 540-550  
 Goffin, V., 498-509  
 Gold, P. W., 717-722  
 Gravanis, A., 425-433  
 Green, P. G., 282-288  
 Griffin, A. C., 705-716  
 Grimm, M. C., 9-20  
 Grossman, A. B., 249-261

**H**adden, J. W., 352-358  
 Hadid, R., 480-490  
 Haour, F., 755-761  
 Harbuz, M. S., 599-607  
 Hawkey, L. C., 664-673  
 Heijnen, C. J., 698-704  
 Heller, P., 282-288  
 Hellhammer, D. H., 747-754  
 Heppner, C., 809-821  
 Holsboer, F., 525-531  
 Hori, T., 269-281  
 Hosoi, M., 269-281  
 Houri, J. M., 762-772  
 Howard, O. M. Z., 9-20  
 Hu, Y., 755-761

**I**ntrona, M., 338-351  
 Ip, N. Y., 97-106

**J**acobs, R. A., 249-261  
 Jafarian-Tehrani, M., 755-761  
 Janig, W., 282-288  
 Jessop, D. S., 599-607  
 Jobst, S., 747-754  
 Jung, J., 803-808

**K**abiersch, A., 123-127  
 Kavelaars, A., 698-704  
 Keane, K. M., 59-64  
 Kecha, O., 328-337  
 Keisler, D., 762-772  
 Kelley, K. W., 518-524, 586-590  
 Kelly, P. A., 498-509  
 Kiecolt-Glaser, J. K., 649-655, 656-663, 664-673  
 Kimura, M., 174-184  
 King, L. B., 317-327  
 Konishi, Y., 107-116  
 Konstantinos, A., 803-808  
 Kostoglou-Athanassiou, I., 249-261  
 Kuis, W., 698-704  
 Kupina, N. C., 59-64  
 Kustova, Y., 822-834

**L**abeur, M. S., 444-455  
 Lafuse, W. P., 773-786  
 Layé, S., 586-590  
 Lechner, O., 591-598  
 Lee, S., 434-443  
 Leeman, S. E., 635-648  
 Letourneau, R., 619-634  
 Leung, D. Y. M., 735-746  
 Levine, J. D., 282-288  
 Li, Y., 822-834  
 Lightman, S. L., 599-607  
 Linthorst, A. C. E., 139-152, 444-455  
 Lipton, J. M., 373-380, 848-856  
 Liu, Q., 518-524

Luger, T. A., 381-394

Lynch, T., 59-64

**M**aaskant, R. A., 498-509

Madden, K. S., 262-268

Maestroni, G. J. M., 395-410, 411-419

Maier, S. F., 289-300

Malarkey, W. B., 649-655, 656-663,  
664-673

Manolagas, S. C., 194-204

Mantovani, A., 338-351

Marchetti, B., 205-248

Margioris, A. N., 425-433

Martens, H., 328-337

McAllen, K., 420-424

McCann, S. M., xiii-xiv, 174-184, 185-193

McEwen, B. S., 33-44, 551-562

McGivern, R. F., 456-469

McKean, D. J., 420-424

McMurray, R. W., 762-772

Meier, W. A., 518-524

Mello-Coelho, V., 510-517

Melmed, S., 162-173

Miao, F. J.-P., 282-288

Michelson, D., 717-722

Minshall, C., 518-524

Monge-Arditi, G., 117-122, 153-161

Moore, P. M., 599-607

Morale, M. C., 205-248

Morse III, H. C., 822-834

Mu, Y., 540-550

Muller, K., 480-490

Muzio, M., 338-351

**N**avarra, P., 249-261

Norbiato, G., 835-847

Nordberg, J., 551-562

**O**ppenheim, J. J., 9-20

Ormandy, C. J., 498-509

**P**adgett, D., 803-808

Páez Pereda, M., 525-531

Pang, X., 619-634

Pankhaniya, R. R., 540-550

Parnet, P., 586-590

Paus, R., 381-394

Perks, P., 599-607

Petzke, F., 809-821

Pierpaoli, W., 491-497

Poehlmann, K. M., 664-673

Poole, S., 128-138

Postel-Vinay, M. C., 510-517

Pothoulakis, C., 635-648

**R**ay, D. W., 162-173

Redei, E., 456-479

Reichlin, S., 301-316

Reincke, M., 809-821

Ren, S.-G., 162-173

Renner, U., 525-531

Rettori, V., 174-184, 185-193

Reul, J. M. H. M., 139-152, 444-455

Revskey, S., 456-469

Rittenhouse, P. A., 456-469

Rivier, C., 434-443

Romeo, C., 205-248

**S**ant, G. R., 619-634

Satta, M. A., 249-261

Sauer, J., 525-531

Savino, W., 470-479

Schacher, D. H., 518-524

Schielke, G. F., 59-64

Schlechte, J. A., 762-772

Schmidt, E. D., 65-73

Scholzen, T., 381-394

Schultzberg, M., 128-138

Sehic, E., 608-618

Sei, Y., 822-834

Sephton, S. E., 674-683

Sgonc, R., 591-598

Shahabi, N. A., 420-424

Shanahan, F., 723-734

Shanks, N., 599-607

Sharp, B. M., 420-424

Sharp, G. C., 762-772

- Sheridan, J. F., 649-655, 664-673, 803-808
- Shirabe, T., 107-116
- Shivers, B. D., 59-64
- Skolnick, P., 822-834
- Slominski, A., 381-394
- Spiegel, D., 674-683
- Spinedi, E., 480-490
- Sreedharan, S. P., 540-550
- Stalla, G. K., 525-531
- Sternberg, E. M., 1-8
- Stites, D. P., 674-683
- Strausbaugh, H., 282-288
- Swiergiel, A. H., 577-585
- Szeffler, S. J., 735-746
- T**abira, T., 107-116
- Taub, D. D., 9-20
- Ternynck, T., 755-761
- Terr, A. I., 674-683
- Testa, N., 205-248
- Theoharides, T. C., 619-634
- ThyagaRajan, S., 262-268
- Tilders, F. J. H., 65-73, 128-138
- Tirollo, C., 205-248
- Torpy, D. J., 21-32
- Touraine, P., 498-509
- Turnbull, A. W., 434-443
- V**acchio, M. S., 317-327
- Vago, T., 835-847
- Van Dam, A.-M., 128-138
- Vandersmissen, E., 328-337
- VanHoy, R., 518-524
- Vartanian, M. G., 59-64
- Vasilakos, J. P., 59-64
- Venihaki, M., 425-433
- Villa-Verde, D. M. S., 470-479
- W**alker, S. E., 762-772
- Wang, J. M., 9-20
- Watkins, L. R., 289-300
- Webster, E., 21-32
- Weimann, E., 498-509
- Weinstock, J. V., 532-539
- Whitacre, C. C., 705-716
- Wick, G., 591-598, 755-761
- Wieggers, G. J., 444-455
- Wilder, R. L., 45-50
- X**ia, M., 540-550
- Y**u, W. H., 174-184
- Z**avala, F., 128-138
- Zwilling, B. S., 773-786

